The recently announced global license agreement with Novartis to advance VAV1-directed MGDs for immune-related conditions marks a transformative milestone towards that goal,” said Markus Warmuth, M.D.

According to the agreement, Vindur Tx will pay Optic up to $17.5 million for its proprietary technology to explore new ways of addressing previously "undruggable" targets in difficult-to-treat cancers ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

“As the year progresses, the market will continue to outperform expectations. Real estate transactions are more robust than last year, with month-on-month growth. The market has demonstrated ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

The Master Services Agreement (MSA) and Clinical Supply Agreement with Nucleus RadioPharma complement the existing agreement with NorthStar Medical Radioisotopes, LLC (NorthStar) for 67Cu-SAR-bisPSMA ...

Doctors have been fairly quick to jump on the biologics train: According to Spherix, 96% of dermatologists reported using ...

Among other pharma bigwigs, Novartis also beat third-quarter earnings and revenue estimates, driven by a year-over-year ...

Dataiku, the Universal AI Platform, today announced that company President Krish Venkataraman will be speaking at Fortune Global Forum 2024, the premier gathering of CEOs and leaders of the world's ...

Watch out, Gilead and Novartis: there's a new CAR-T in town. Autolus is ready to hit the ground running after winning FDA approval for its Aucatzyl, a late entry to the heated CD19 CAR-T cell therapy ...

Women aged less than 50 years hospitalized with MI have gender-specific cardiovascular risk factors and experience typical chest pain.

SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...